Abbey B Berenson1, Jacqueline M Hirth, Mihyun Chang. 1. Center for Interdisciplinary Research in Women's Health and the Department of Obstetrics & Gynecology, the University of Texas Medical Branch, Galveston, Texas.
Abstract
OBJECTIVE: To examine changes in prevalence of vaginal human papillomavirus (HPV) between 2009-2010 and 2013-2014 among both vaccinated and unvaccinated U.S. women. METHODS: We evaluated HPV prevalence among women 18-59 years old using cross-sectional survey data from three different cycles of the National Health and Nutrition Examination Survey. Data were stratified into four age groups (18-26, 27-34, 35-44, and 45-49 years) to examine trends over time among women of different ages in the postvaccine era. Multivariable analyses, which controlled for descriptive variables, were used to examine the prevalence of quadrivalent vaccine-type HPV by vaccination status. RESULTS: We observed a significant decrease in the prevalence of vaccine-type HPV among women 18-59 years of age from 2009-2010 to 2013-2014. This decline was only significant in those 18-26 years old when the sample was stratified into the four age groups. Among vaccinated 18-26 year olds, HPV prevalence remained low from 2009-2010 (3.9%) to 2013-2014 (2.0%; prevalence ratio 0.51, 95% CI 0.18-1.46). Unvaccinated women 18-26 years old also demonstrated a significant decrease over time from 19.5% in 2009-2010 to 9.7% in 2013-2014 (prevalence ratio 0.44, 95% CI 0.22-0.91). Prevalence did not significantly change among unvaccinated women 26 years old or older. CONCLUSIONS: The decline in HPV infections among unvaccinated 18- to 26-year-old women suggests that young women in the United States are beginning to benefit from herd immunity resulting from the introduction of the HPV vaccine.
OBJECTIVE: To examine changes in prevalence of vaginal human papillomavirus (HPV) between 2009-2010 and 2013-2014 among both vaccinated and unvaccinated U.S. women. METHODS: We evaluated HPV prevalence among women 18-59 years old using cross-sectional survey data from three different cycles of the National Health and Nutrition Examination Survey. Data were stratified into four age groups (18-26, 27-34, 35-44, and 45-49 years) to examine trends over time among women of different ages in the postvaccine era. Multivariable analyses, which controlled for descriptive variables, were used to examine the prevalence of quadrivalent vaccine-type HPV by vaccination status. RESULTS: We observed a significant decrease in the prevalence of vaccine-type HPV among women 18-59 years of age from 2009-2010 to 2013-2014. This decline was only significant in those 18-26 years old when the sample was stratified into the four age groups. Among vaccinated 18-26 year olds, HPV prevalence remained low from 2009-2010 (3.9%) to 2013-2014 (2.0%; prevalence ratio 0.51, 95% CI 0.18-1.46). Unvaccinated women 18-26 years old also demonstrated a significant decrease over time from 19.5% in 2009-2010 to 9.7% in 2013-2014 (prevalence ratio 0.44, 95% CI 0.22-0.91). Prevalence did not significantly change among unvaccinated women 26 years old or older. CONCLUSIONS: The decline in HPV infections among unvaccinated 18- to 26-year-old women suggests that young women in the United States are beginning to benefit from herd immunity resulting from the introduction of the HPV vaccine.
Authors: Elyse O Kharbanda; Gabriela Vazquez-Benitez; Heather S Lipkind; Sangini S Sheth; Jingyi Zhu; Allison L Naleway; Nicola P Klein; Rulin Hechter; Matthew F Daley; James G Donahue; Michael L Jackson; Alison Tse Kawai; Lakshmi Sukumaran; James D Nordin Journal: Obstet Gynecol Date: 2018-07 Impact factor: 7.661
Authors: Chelse Spinner; Lili Ding; David I Bernstein; Darron R Brown; Eduardo L Franco; Courtney Covert; Jessica A Kahn Journal: Pediatrics Date: 2019-01-22 Impact factor: 7.124
Authors: Jacqueline M Hirth; Yong-Fang Kuo; Jonathan M Starkey; Richard E Rupp; Tabassum H Laz; Mahbubur Rahman; Abbey B Berenson Journal: Vaccine Date: 2019-06-07 Impact factor: 3.641
Authors: Lea E Widdice; David I Bernstein; Eduardo L Franco; Lili Ding; Darron R Brown; Aaron C Ermel; Lisa Higgins; Jessica A Kahn Journal: Vaccine Date: 2019-09-30 Impact factor: 3.641
Authors: Jacqueline Hirth; Christine J McGrath; Yong-Fang Kuo; Richard E Rupp; Jonathan M Starkey; Abbey B Berenson Journal: Vaccine Date: 2018-10-28 Impact factor: 3.641